Can drug stocks outperform the market based on a strong earnings outlook?

Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Before we present a few large drug stocks that are well-positioned to outperform the market based on a strong earnings outlook, let’s take a look at the industry’s performance and its current valuation.

Is Schrödinger a good drug discovery stock?

Of the three, Schrödinger seems to be the safest bet if you're looking to benefit from the growth in drug discovery stocks that use AI. The company has two different avenues to cash in on machine learning and has already shown it can bring drugs to the market and turn a profit.

Will innovation drive growth in the drug industry in 2023?

Overall, innovation is likely to drive growth in the industry in 2023. M&A deals are also picking up, which shows growth. Among the large drugmakers, J&J JNJ, Novo Nordisk NVO, AstraZeneca AZN, Novartis NVS and Sanofi SNY are worth retaining in your portfolio.